Original language | English |
---|---|
Pages (from-to) | 1282-1288 |
Number of pages | 7 |
Journal | Cancer immunology research |
Volume | 10 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer immunology research, Vol. 10, No. 11, 11.2022, p. 1282-1288.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - The AACR Journals
T2 - Advancing Progress Toward the AACR's 115-Year Mission
AU - Anderson, Kenneth C.
AU - Cantley, Lewis C.
AU - Dalla-Favera, Riccardo
AU - Van Dang, Chi
AU - Diaz, Luis A.
AU - DuBois, Raymond N.
AU - Flaherty, Keith T.
AU - Greenberg, Philip D.
AU - Loda, Massimo
AU - Mardis, Elaine R.
AU - Platz, Elizabeth A.
AU - Pollak, Michael N.
AU - Schreiber, Robert D.
AU - Siu, Lillian L.
AU - Teicher, Beverly A.
N1 - Funding Information: L. Cantley consulted for Petra Pharmaceuticals, Agios Pharmaceuticals, EIP Pharmaceuticals, Volastra, Larkspur, and Cell Signaling Technologies over the past year. He also received grant support from the NIH/NCI, Gray Foundation, The Mark Foundation, the Breast Cancer Research Foundation, and Stand Up To Cancer/ American Association for Cancer Research over the past year, and is a stockholder in Agios Pharmaceuticals, EIP Pharmaceuticals, Cell Signaling Technologies, Volastra, and Larkspur. R. Dalla-Favera is a consultant for NeoGenomics and AstraZeneca and receives research funds from AstraZeneca. L.A. Diaz is a member of the board of directors of Jounce Therapeutics and Epitope and is a compensated consultant to PetDx, Innovatus CP, Se’er, Delfi, Blackstone, Kinnate, and Neophore. He is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy; some of these licenses and relationships are associated with equity or royalty payments directly to the inventors. He holds equity in Epitope, Jounce Therapeutics, PetDx, Se’er, Delfi, Kinnate, and Neophore; he divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and he divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict of interest policies. K.T. Flaherty reports personal fees from Clovis Oncology, Checkmate Pharmaceuticals, Strata Oncology, Kinnate Biopharma, Scorpion Therapeutics, PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures,
PY - 2022/11
Y1 - 2022/11
UR - http://www.scopus.com/inward/record.url?scp=85141181940&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-22-0782
DO - 10.1158/2326-6066.CIR-22-0782
M3 - Editorial
C2 - 36321298
AN - SCOPUS:85141181940
SN - 2326-6066
VL - 10
SP - 1282
EP - 1288
JO - Cancer immunology research
JF - Cancer immunology research
IS - 11
ER -